Seres Therapeutics Inc
NASDAQ:MCRB 3:59:52 PM EDT
Products, Regulatory
Seres Therapeutics Enrolls 300 Subjects In Phase 3 Study Of Recurrent C. Difficile Infection Treatment
Published: 09/15/2021 11:21 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Achieves Enrollment of 300 Subjects With Phase 3 Ecospor Iv Open-label Extension Study of Ser-109, a Potentially First-in-class Investigational Microbiome Therapeutic for Recurrent C. Difficile Infection.
Seres Therapeutics - Expects Completed Phase 3 Study Results and Pending Open-label Study Database to Finalize Bla Filing in Mid-2022.
Seres Therapeutics - Expects Completed Phase 3 Study Results and Pending Open-label Study Database to Finalize Bla Filing in Mid-2022.